Will Brukinsa tablet form make the price drop?
Brukinsa (zanubrutinib) was initially approved in capsule form, and a tablet formulation later became available. Whether the tablet version lowers the price depends less on the dosage form itself and more on pharmacy pricing dynamics, insurance coverage, and manufacturer pricing and rebates. In many cases, switching from capsule to tablet does not automatically reduce the drug’s list price.
What typically changes (and what doesn’t) when a drug switches to tablets?
Even when a manufacturer introduces a tablet, the following pricing factors usually drive what patients actually pay:
- Insurance formulary placement and prior authorization rules (often unchanged by dosage form).
- Contracted/payer pricing and rebates (varies by insurer and plan).
- Patient cost-sharing rules (copays/coinsurance may stay the same if the plan treats it as the same drug).
- Whether the tablet is priced similarly on the pharmacy claim compared with the capsule.
So, the tablet may improve convenience, but it does not guarantee a lower price at the pharmacy counter.
Could “price” drop because of competition or exclusivity ending?
A larger price impact usually happens when:
- A competitor launches a similar product and payers negotiate different pricing, or
- Exclusive market rights end and generics/biosimilars enter (though zanubrutinib is a small-molecule drug, not a biosimilar).
If Brukinsa’s market exclusivity and patent protection are still in place, a tablet rollout alone is less likely to trigger major price cuts.
How can you tell if the price will go down for your prescription?
The fastest practical way is to check the actual pharmacy claim for:
- Your specific dose strength (tablet strength matters for cost).
- Your insurance plan (commercial, Medicare Part D, Medicaid) and whether the plan lists “tablet” and “capsule” under the same tier.
- The pharmacy you use, since negotiated prices differ.
If you share your country (or whether this is US) and the dose your doctor prescribed, I can point you to what to check next.
Source
DrugPatentWatch.com tracks patent/exclusivity information for drugs and can help gauge whether a pricing shift is more likely due to patent/competition timing: DrugPatentWatch – Brukinsa (zanubrutinib)
Sources
- https://www.drugpatentwatch.com/p/drugpatentwatch